Recombinant Staphylococcus aureus 3-oxoacyl-[acyl-carrier-protein] synthase 3 (fabH)

What is Staphylococcus aureus FabH and what role does it play in bacterial metabolism?

Staphylococcus aureus FabH (saFabH) is a β-ketoacyl-acyl carrier protein (ACP) synthase III enzyme that plays an essential role in bacterial fatty acid biosynthesis. It catalyzes the initial condensation reaction in the bacterial type II fatty acid synthase (FAS) system, specifically performing a decarboxylative condensation between malonyl-ACP and an acyl coenzyme A (CoA) substrate . This reaction initiates the elongation cycle in fatty acid biosynthesis, making FabH essential for bacterial viability. In the context of S. aureus pathogenicity, the enzyme is crucial for membrane phospholipid formation, which directly impacts bacterial survival, virulence, and antibiotic resistance mechanisms .

How does S. aureus FabH differ from FabH enzymes in other bacterial species?

S. aureus FabH (saFabH) exhibits significant sequence homology with FabH proteins from other bacterial species but demonstrates important structural and functional differences. Specifically, saFabH shows 57% amino acid sequence identity with Bacillus subtilis FabH1 (bFabH1), 40% with Escherichia coli FabH (ecFabH), and 34% with other bacterial FabH proteins . These differences manifest in substrate specificity and catalytic efficiency. While E. coli FabH predominantly utilizes acetyl-CoA as a substrate, saFabH demonstrates broader substrate specificity, accepting both straight-chain and branched-chain acyl-CoA primers . This substrate versatility contributes to the diverse fatty acid profiles observed in S. aureus membranes and represents an evolutionary adaptation to different environmental conditions and nutrient availability.

What are the optimal conditions for cloning and expressing recombinant S. aureus FabH?

For optimal cloning and expression of recombinant S. aureus FabH, researchers should follow this methodological approach:

• Gene amplification: PCR-amplify the S. aureus fabH gene using primers that introduce appropriate restriction sites (similar to the approach used for B. subtilis fabH where XhoI/NdeI and BamHI sites were introduced) .

• Vector selection: Clone the amplified gene into an expression vector containing an inducible promoter (typically T7) and an antibiotic resistance marker.

• Expression conditions:

  • Transform the construct into an E. coli expression strain (typically BL21(DE3) or derivatives)

  • Grow transformed cells on LB agar supplemented with appropriate antibiotic (e.g., 100 μg/ml ampicillin)

  • Screen colonies for overexpression using SDS-PAGE

  • Inoculate positive colonies into LB medium with antibiotic

  • Grow culture at 37°C with shaking (250 rpm) until OD600 reaches 0.8

  • Induce expression with 1 mM isopropyl β-D-thiogalactoside (IPTG)

  • Continue incubation at a reduced temperature (30°C) for 12 hours to enhance protein solubility

This protocol typically yields sufficient quantities of soluble, enzymatically active saFabH protein for biochemical and structural studies.

What purification strategy yields the highest activity of recombinant S. aureus FabH?

A multi-step purification strategy is recommended to obtain high-purity, enzymatically active recombinant S. aureus FabH:

• Cell lysis: Harvest cells by centrifugation (10,000 × g) and disrupt using either sonication or French press in a buffer containing protease inhibitors .

• Initial purification: Apply the clarified lysate to a nickel affinity column if a His-tag was incorporated, or use ion exchange chromatography as the initial capture step.

• Intermediate purification: Subject the protein to size exclusion chromatography to remove aggregates and further enhance purity.

• Activity preservation: Include reducing agents (1-5 mM β-mercaptoethanol or DTT) in all buffers to protect the catalytic cysteine residue (Cys111) from oxidation .

• Storage conditions: Store the purified enzyme in buffer containing 10-20% glycerol at -80°C, avoiding repeated freeze-thaw cycles which can reduce enzymatic activity.

This approach typically yields enzyme preparations with >95% purity and high specific activity suitable for kinetic, structural, and inhibitor screening studies.

What assays are available for measuring S. aureus FabH activity in vitro?

Two complementary assay systems have been validated for measuring S. aureus FabH activity in vitro:

• Radioactive filter disc assay:

  • Reaction mixture components: 100 μM ACP, 70 μM malonyl-CoA, 50 μM [1-14C]acetyl-CoA (specific activity ~46 Ci/mol), 0.2 μg E. coli FabD, and 0.1 M sodium phosphate buffer (pH 7.0)

  • Initiate reaction by adding FabH and incubate at 37°C for 12 minutes

  • Transfer 35-μl aliquots to Whatman 3MM filter discs and wash with decreasing concentrations of ice-cold trichloroacetic acid (10%, 5%, and 1%)

  • Dry filters and quantify radioactivity using scintillation counting

• Gel electrophoresis-based assay:

  • Reaction mixture: 25 μM ACP, 1 mM β-mercaptoethanol, 70 μM [2-14C]malonyl-CoA, and acyl-CoA primer

  • Separate reaction products using conformationally-sensitive gel electrophoresis

  • Visualize and quantify products using phosphorimaging

The filter disc assay is more suitable for high-throughput screening, while the gel-based approach provides detailed information on reaction intermediates and is valuable for mechanistic studies.

How does the catalytic mechanism of S. aureus FabH operate?

The catalytic mechanism of S. aureus FabH follows a three-step Ping-Pong reaction mechanism, as elucidated through studies of homologous enzymes like Cuphea wrightii KAS III:

• Acyl-enzyme formation: The catalytic Cys111 residue performs a nucleophilic attack on the acyl-CoA substrate, forming a thioester intermediate with release of CoA.

• Decarboxylation of malonyl-ACP: His261 functions as a general base to facilitate the decarboxylation of malonyl-ACP, generating a carbanion intermediate.

• Claisen condensation: The carbanion attacks the acyl-enzyme thioester, forming the β-ketoacyl-ACP product, which is released from the enzyme .

Key residues in this mechanism include:

• Cys111: Forms the acyl-enzyme intermediate (replacement with Ala or Ser abolishes condensing activity)

• His261: Functions as both general base and acid in the catalytic cycle (replacement with Ala eliminates activity, while Arg substitution retains function)

• Arg150 and Arg306: Participate in substrate binding and catalysis

This mechanism is conserved across FabH enzymes but exhibits distinct substrate preferences that influence the fatty acid composition of bacterial membranes.

What screening approaches are effective for identifying novel S. aureus FabH inhibitors?

Effective screening approaches for identifying novel S. aureus FabH inhibitors include:

• High-throughput biochemical assays:

  • Filter disc-based radiometric assay using [14C]acetyl-CoA to quickly evaluate large compound libraries

  • Fluorescence-based assays monitoring either CoA release or product formation with suitable fluorescent probes

• Structure-guided screening:

  • In silico docking against the crystal structure or homology model of saFabH

  • Fragment-based screening focusing on the active site containing Cys111 and His261

• Phenotypic screening with target validation:

  • Whole-cell screening against S. aureus strains

  • Secondary biochemical assays to confirm on-target activity

  • Testing against S. aureus strains with FabH overexpression to confirm mechanism of action

Research has already identified two compounds that inhibit saFabH up to 100-fold more effectively than thiolactomycin (TLM), a known FabH inhibitor . These compounds provide valuable starting points for structure-based design of improved inhibitors with enhanced potency and selectivity.

How can researchers address potential resistance mechanisms when developing FabH inhibitors?

Addressing potential resistance mechanisms for FabH inhibitors requires a multi-faceted approach:

Implementing these strategies during inhibitor development will increase the likelihood of creating therapeutically viable agents with reduced resistance potential.

How can site-directed mutagenesis be used to probe the structure-function relationship of S. aureus FabH?

Site-directed mutagenesis offers a powerful approach to probe structure-function relationships in S. aureus FabH:

This approach has successfully dissected the condensing reaction into three stages (acyl-enzyme formation, decarboxylation, and Claisen condensation) in homologous enzymes, providing a framework for understanding saFabH catalysis .

What techniques can be used to study the interaction between S. aureus FabH and potential inhibitors?

Multiple complementary techniques can be employed to characterize S. aureus FabH-inhibitor interactions:

• Enzyme kinetic studies:

  • Determine inhibition constants (Ki) and inhibition mechanisms (competitive, noncompetitive, uncompetitive)

  • Conduct time-dependent inhibition studies to identify slow-binding or irreversible inhibitors

  • Perform substrate protection experiments to locate the inhibitor binding site

• Biophysical binding assays:

  • Thermal shift assays (TSA) to measure inhibitor-induced stabilization of FabH

  • Isothermal titration calorimetry (ITC) to quantify binding thermodynamics (ΔH, ΔS, ΔG)

  • Surface plasmon resonance (SPR) to determine association and dissociation rates

• Structural biology approaches:

  • X-ray crystallography of FabH-inhibitor complexes to visualize binding modes

  • NMR spectroscopy to map inhibitor binding sites and detect conformational changes

  • Hydrogen-deuterium exchange mass spectrometry (HDX-MS) to identify regions protected by inhibitor binding

• Computational methods:

  • Molecular dynamics simulations to study inhibitor binding and protein dynamics

  • Free energy calculations to estimate binding affinities

  • Virtual screening to identify new inhibitor scaffolds

These techniques provide complementary information about inhibitor potency, selectivity, binding mode, and mechanism of action, guiding rational optimization of inhibitor structures for improved properties.

How does the fatty acid profile of S. aureus change during infection, and what implications does this have for FabH inhibitor efficacy?

Research using lipidomics approaches has revealed significant changes in S. aureus fatty acid profiles during infection:

• Observed changes at infection sites:

  • Significantly reduced branched-chain fatty acid content

  • Increased even-chain fatty acid content

  • These changes occur compared to growth in rich laboratory media

• Environmental factors driving these changes:

  • Limited isoleucine availability at infection sites

  • Presence of exogenous host fatty acids

  • These conditions can be reproduced in the laboratory using isoleucine-deficient medium containing exogenous fatty acids

• Metabolic adaptation mechanisms:

  • S. aureus utilizes the fatty acid kinase (Fak) system to incorporate host fatty acids

  • FakB2 is required for oleate assimilation

  • FakB1 affects the balance of saturated fatty acids and enhances oleate utilization

• Implications for FabH inhibitor efficacy:

  • Despite utilizing host fatty acids, S. aureus still requires de novo fatty acid synthesis for membrane phospholipid construction

  • Specifically, pentadecanoic acid (a branched-chain fatty acid derived from isoleucine or leucine) is essential and predominantly occupies the 2-position of S. aureus phospholipids

  • This suggests that FabH inhibitors would remain effective at infection sites, as they would block this essential de novo synthesis pathway

These findings indicate that FabH inhibitors should be evaluated under conditions mimicking the infection site (isoleucine limitation with exogenous fatty acids) to accurately predict their in vivo efficacy.

What methodological approaches can be used to study the in vivo efficacy of FabH inhibitors?

Comprehensive evaluation of FabH inhibitors' in vivo efficacy requires a multi-faceted methodological approach:

• Infection models:

  • Mouse thigh infection model - allows for direct assessment of bacterial burden and collection of S. aureus for membrane composition analysis

  • Systemic infection models - evaluate inhibitor efficacy in multiple tissue types

  • Biofilm infection models - test efficacy against S. aureus in biofilm state, which may have altered membrane composition

• Pharmacokinetic (PK) and pharmacodynamic (PD) assessment:

  • Determine inhibitor stability, distribution, and tissue penetration

  • Establish PK/PD relationships to optimize dosing regimens

  • Measure inhibitor concentrations at infection sites relative to minimum inhibitory concentration

• Target engagement verification:

  • Lipidomics analysis of bacterial cells recovered from infection sites before and after inhibitor treatment

  • Changes in fatty acid profiles, particularly pentadecanoic acid levels, can confirm on-target activity

  • Comparison with profiles of FabH-depleted strains can validate mechanism of action

• Resistance development assessment:

  • Serial passage studies in laboratory media supplemented with host-relevant fatty acids

  • Evaluation of resistance development rates in animal models during extended treatment

  • Whole genome sequencing of resistant isolates to identify resistance mechanisms

• Combination therapy evaluation:

  • Test FabH inhibitors in combination with existing antibiotics

  • Assess synergy with inhibitors of fatty acid kinase to block both de novo synthesis and exogenous fatty acid utilization

  • Determine optimal combination strategies to prevent resistance development

This comprehensive approach ensures that promising inhibitors identified in biochemical assays can be effectively translated into clinically viable therapeutic agents.

What are the common challenges in purifying active recombinant S. aureus FabH, and how can they be overcome?

Researchers frequently encounter several challenges when purifying active recombinant S. aureus FabH:

• Protein solubility issues:

  • Challenge: Formation of inclusion bodies during overexpression

  • Solution: Lower induction temperature to 30°C or 20°C; reduce IPTG concentration to 0.1-0.5 mM; use specialized E. coli strains designed for improved protein folding; co-express with molecular chaperones

• Oxidation of catalytic cysteine:

  • Challenge: The essential Cys111 residue is susceptible to oxidation, resulting in loss of activity

  • Solution: Include reducing agents (5-10 mM β-mercaptoethanol or 1-2 mM DTT) in all purification and storage buffers; perform purification under nitrogen atmosphere when possible; add reducing agents fresh before each experiment

• Protein instability:

  • Challenge: Loss of activity during purification and storage

  • Solution: Add 10-20% glycerol to storage buffers; maintain pH between 7.0-7.5; store at -80°C in small aliquots to avoid repeated freeze-thaw cycles; consider adding protease inhibitors during purification

• Co-purification of E. coli proteins:

  • Challenge: Contamination with E. coli FabH or other fatty acid synthesis enzymes

  • Solution: Include multiple chromatography steps in purification (affinity, ion-exchange, and size exclusion); consider using affinity tags positioned to minimize interference with enzyme activity; verify purity by mass spectrometry

• Low expression levels:

  • Challenge: Insufficient protein yield for biochemical studies

  • Solution: Optimize codon usage for E. coli expression; use high-copy-number plasmids with strong promoters; screen multiple expression strains and conditions; consider fusion partners that enhance expression and solubility

Addressing these challenges systematically will significantly improve the quality and quantity of purified recombinant saFabH for subsequent biochemical and structural studies.

How can researchers address the challenge of substrate availability for S. aureus FabH assays?

Ensuring substrate availability for S. aureus FabH assays presents several challenges that researchers can address through these methodological approaches:

• Acyl carrier protein (ACP) preparation:

  • Challenge: Obtaining sufficient quantities of correctly folded holo-ACP

  • Solution: Express and purify ACP from E. coli; convert apo-ACP to holo-ACP using recombinant ACP synthase and CoA; alternatively, purchase commercially available ACP; validate by mass spectrometry to confirm correct post-translational modification

• Malonyl-ACP generation:

  • Challenge: Malonyl-ACP is unstable and difficult to isolate

  • Solution: Generate malonyl-ACP in situ using purified malonyl-CoA:ACP transacylase (FabD) and malonyl-CoA; alternatively, use [2-14C]malonyl-CoA in coupled enzyme assays with FabD

• Radioisotope handling:

  • Challenge: Many FabH assays require radioisotopes ([14C]acetyl-CoA or [14C]malonyl-CoA)

  • Solution: Develop non-radioactive alternatives such as HPLC-based assays, fluorescence assays measuring CoA release, or mass spectrometry-based methods; ensure proper safety protocols when using radioisotopes

• Branched-chain acyl-CoA primers:

  • Challenge: Limited commercial availability of branched-chain acyl-CoA substrates

  • Solution: Synthesize these substrates enzymatically using acyl-CoA synthetase with appropriate fatty acid precursors; verify purity by HPLC or mass spectrometry; alternatively, establish collaborations with chemical synthesis groups for custom substrate preparation

• Assay interference:

  • Challenge: Compounds in inhibitor screens may interfere with detection methods

  • Solution: Include appropriate controls to detect assay interference; develop orthogonal assay formats to confirm hits; use purified enzyme systems to minimize non-specific effects

By implementing these methodological solutions, researchers can overcome substrate availability challenges and establish robust, reproducible assay systems for studying S. aureus FabH.

What are the promising approaches for developing dual-target inhibitors that affect both FabH and other fatty acid synthesis enzymes?

Several promising approaches can be pursued for developing dual-target inhibitors affecting both FabH and other fatty acid synthesis enzymes:

• Pharmacophore-based design:

  • Analyze binding site similarities between FabH and other FAS enzymes (FabB/F, FabI)

  • Identify common structural features that can be incorporated into inhibitor design

  • Develop hybrid molecules containing elements that interact with both targets

• Fragment-based drug discovery:

  • Screen fragment libraries against multiple FAS enzymes

  • Identify fragments that bind to both FabH and other targets

  • Link or grow these fragments to create dual-target inhibitors

  • Validate binding to both targets using biophysical methods (X-ray crystallography, NMR, SPR)

• Structure-guided design:

  • Leverage structural similarities in the active sites of FabH and FabB/F enzymes

  • Focus on the catalytic triad (Cys-His-Asn/His) present in multiple condensing enzymes

  • Design inhibitors that can adopt different binding modes in each target

• Natural product derivatives:

  • Thiolactomycin analogs have shown activity against both FabH and FabB/F enzymes

  • Platensimycin-inspired compounds may be modified to increase FabH affinity while maintaining activity against FabF

  • Cerulenin derivatives could be optimized for dual targeting

• Covalent inhibitor approaches:

  • Design inhibitors that can form covalent bonds with the catalytic cysteine present in multiple FAS enzymes

  • Incorporate electrophilic warheads with appropriate reactivity and selectivity

  • Use targeted covalent inhibitor approaches to enhance potency and residence time

This multi-target approach could potentially overcome resistance mechanisms and increase therapeutic efficacy compared to single-target FabH inhibitors.

How might systems biology approaches enhance our understanding of FabH's role in S. aureus pathogenesis?

Systems biology approaches offer powerful tools to comprehensively understand FabH's role in S. aureus pathogenesis:

• Multi-omics integration:

  • Combine transcriptomics, proteomics, and lipidomics data from S. aureus under various conditions

  • Profile changes during infection, antibiotic treatment, and FabH inhibition

  • Correlate membrane lipid composition with virulence factor expression and antibiotic susceptibility

• Metabolic flux analysis:

  • Use 13C-labeled precursors to trace carbon flow through fatty acid biosynthesis pathways

  • Quantify the relative contribution of de novo synthesis versus fatty acid assimilation

  • Identify metabolic bottlenecks and potential compensatory pathways during FabH inhibition

• Mathematical modeling:

  • Develop computational models of S. aureus fatty acid metabolism

  • Simulate the effects of FabH inhibition under various environmental conditions

  • Predict potential resistance mechanisms and compensatory pathways

• Genome-scale interaction studies:

  • Perform genetic interaction screens to identify synthetic lethal partners of FabH

  • Map the genetic interaction network of fatty acid synthesis genes

  • Identify potential combination therapy targets based on synthetic lethality

• Host-pathogen interaction analysis:

  • Study how S. aureus membrane composition affects host immune recognition

  • Investigate the relationship between fatty acid composition and immune evasion

  • Determine how host fatty acid availability influences virulence gene expression

These systems-level approaches would provide a comprehensive understanding of FabH's role beyond its enzymatic function, potentially revealing unexpected connections to virulence, antibiotic resistance, and metabolic adaptation during infection.

How does the substrate specificity of S. aureus FabH compare with FabH enzymes from other clinically relevant pathogens?

A comparative analysis of substrate specificity between S. aureus FabH and those from other clinically relevant pathogens reveals important differences:

The substrate specificity differences correlate with distinct membrane compositions:

• S. aureus FabH: Demonstrates versatility in accepting both acetyl-CoA and branched-chain acyl-CoA substrates, contributing to the adaptable membrane fatty acid profile that includes both straight-chain and branched-chain fatty acids .

• E. coli FabH: Highly specific for acetyl-CoA, resulting in predominantly straight-chain fatty acids in the membrane .

• B. subtilis FabH system: Contains two FabH homologs (FabH1 and FabH2) with complementary activities - FabH1 preferring branched-chain substrates and FabH2 having broader specificity .

These substrate specificity differences present opportunities for developing selective inhibitors targeting specific pathogens based on their unique FabH characteristics.

What structural features of the S. aureus FabH active site can be exploited for selective inhibitor design?

The S. aureus FabH active site contains several unique structural features that can be exploited for selective inhibitor design:

• Catalytic triad configuration:

  • saFabH contains a Cys111-His261-Asn/His catalytic triad with specific spatial arrangements that differ subtly from other bacterial FabH enzymes

  • The orientation and distance between these residues can be targeted for selective inhibitor design

• Substrate binding pocket characteristics:

  • saFabH accommodates both straight-chain and branched-chain acyl-CoA primers

  • The acyl-binding pocket is deeper and more flexible than in E. coli FabH

  • These differences in pocket geometry can be exploited for selectivity

• Unique residues near the active site:

  • Arg150 and Arg306 participate in substrate binding and catalysis in saFabH

  • These residues may be positioned differently compared to homologous enzymes

  • Inhibitors can be designed to interact with these unique structural elements

• CoA binding site features:

  • The CoA binding site contains several charged and polar residues that differ among FabH enzymes

  • Inhibitors extending into this region can gain selectivity through specific interactions with these residues

• Allosteric sites:

  • Potential allosteric sites unique to saFabH may exist

  • These sites could offer highly selective inhibition without targeting the conserved active site

By targeting these structural differences, researchers can design inhibitors with enhanced selectivity for S. aureus FabH over human fatty acid synthase and FabH enzymes from commensal bacteria, potentially reducing off-target effects and adverse impacts on the microbiome.

What are the most significant recent advances in S. aureus FabH research?

Recent significant advances in S. aureus FabH research have expanded our understanding of this enzyme's role in bacterial physiology and antimicrobial resistance:

• Mechanistic insights: Detailed elucidation of the three-step Ping-Pong reaction mechanism involving acyl-enzyme formation, decarboxylation of malonyl-ACP, and Claisen condensation has provided a molecular framework for understanding FabH catalysis .

• Inhibitor discovery: Identification of compounds that inhibit saFabH up to 100-fold more effectively than thiolactomycin (TLM) has established promising starting points for development of potent and selective inhibitors .

• Membrane adaptation during infection: Lipidomics studies have revealed that S. aureus significantly alters its membrane fatty acid composition during infection, with reduced branched-chain fatty acids and increased even-chain fatty acids compared to laboratory growth conditions .

• Essential role despite fatty acid scavenging: Despite S. aureus's ability to utilize host fatty acids via the fatty acid kinase system, research has demonstrated that the bacterium still requires de novo fatty acid biosynthesis initiated by isoleucine or leucine to produce essential pentadecanoic acid .

• Structure-function relationships: Identification of key residues like Cys111, His261, Arg150, and Arg306 in the catalytic mechanism has provided targets for rational inhibitor design and engineering of FabH variants with altered substrate specificity .

These advances collectively validate S. aureus FabH as a promising target for novel antibiotics and provide critical insights for structure-based design of selective inhibitors with therapeutic potential against multidrug-resistant S. aureus infections.

What critical knowledge gaps remain in our understanding of S. aureus FabH, and how might future research address these?

Despite significant advances, several critical knowledge gaps remain in our understanding of S. aureus FabH that future research should address:

• High-resolution structural information:

  • Gap: Lack of high-resolution crystal structures of S. aureus FabH, particularly in complex with substrates or inhibitors

  • Future approach: Apply advanced crystallography and cryo-EM techniques to determine structures in different catalytic states; utilize molecular dynamics simulations to model protein flexibility and substrate binding

• Regulation mechanisms:

  • Gap: Limited understanding of how FabH expression and activity are regulated during infection and antibiotic stress

  • Future approach: Apply systems biology approaches to map transcriptional, translational, and post-translational regulation networks; investigate potential allosteric regulators of enzyme activity

• Role in biofilm formation:

  • Gap: Unknown contributions of FabH and membrane fatty acid composition to biofilm formation and persistence

  • Future approach: Create conditional FabH mutants to study the impact on biofilm development; perform lipidomics analysis of biofilm versus planktonic cells; test FabH inhibitors against biofilm-associated infections

• Resistance mechanism prediction:

  • Gap: Incomplete understanding of potential resistance mechanisms against FabH inhibitors

  • Future approach: Conduct directed evolution experiments to identify resistance mutations; perform whole genome sequencing of resistant mutants; develop computational models to predict resistance pathways

• In vivo efficacy validation:

  • Gap: Limited data on in vivo efficacy of FabH inhibitors in clinically relevant infection models

  • Future approach: Evaluate lead compounds in different animal infection models; optimize pharmacokinetic properties for effective tissue penetration; conduct combination studies with existing antibiotics